Literature DB >> 23462183

Dissecting cellular responses to irradiation via targeted disruptions of the ATM-CHK1-PP2A circuit.

Stela S Palii1, Yuxia Cui, Cynthia L Innes, Richard S Paules.   

Abstract

Exposure of proliferating cells to genotoxic stresses activates a cascade of signaling events termed the DNA damage response (DDR). The DDR preserves genetic stability by detecting DNA lesions, activating cell cycle checkpoints and promoting DNA damage repair. The phosphoinositide 3-kinase-related kinases (PIKKs) ataxia telangiectasia-mutated (ATM), ATM and Rad 3-related kinase (ATR) and DNA-dependent protein kinase (DNA-PK) are crucial for sensing lesions and signal transduction. The checkpoint kinase 1 (CHK1) is a traditional ATR target involved in DDR and normal cell cycle progression and represents a pharmacological target for anticancer regimens. This study employed cell lines stably depleted for CHK1, ATM or both for dissecting cross-talk and compensatory effects on G(2)/M checkpoint in response to ionizing radiation (IR). We show that a 90% depletion of CHK1 renders cells radiosensitive without abrogating their IR-mediated G(2)/M checkpoint arrest. ATM phosphorylation is enhanced in CHK1-deficient cells compared with their wild-type counterparts. This correlates with lower nuclear abundance of the PP2A catalytic subunit in CHK1-depleted cells. Stable depletion of CHK1 in an ATM-deficient background showed only a 50% reduction from wild-type CHK1 protein expression levels and resulted in an additive attenuation of the G(2)/M checkpoint response compared with the individual knockdowns. ATM inhibition and 90% CHK1 depletion abrogated the early G(2)/M checkpoint and precluded the cells from mounting an efficient compensatory response to IR at later time points. Our data indicates that dual targeting of ATM and CHK1 functionalities disrupts the compensatory response to DNA damage and could be exploited for developing efficient anti-neoplastic treatments.

Entities:  

Keywords:  DNA damage; ataxia telangiectasia mutated; checkpoint kinase-1; feedback regulation; phosphatase

Mesh:

Substances:

Year:  2013        PMID: 23462183      PMCID: PMC3646866          DOI: 10.4161/cc.24127

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  49 in total

1.  Single-agent inhibition of Chk1 is antiproliferative in human cancer cell lines in vitro and inhibits tumor xenograft growth in vivo.

Authors:  Kurtis D Davies; Michael J Humphries; Francis X Sullivan; Ira von Carlowitz; Yvan Le Huerou; Peter J Mohr; Bin Wang; James F Blake; Michael A Lyon; Indrani Gunawardana; Mark Chicarelli; Eli Wallace; Stefan Gross
Journal:  Oncol Res       Date:  2011       Impact factor: 5.574

2.  Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability.

Authors:  A Menoyo; H Alazzouzi; E Espín; M Armengol; H Yamamoto; S Schwartz
Journal:  Cancer Res       Date:  2001-11-01       Impact factor: 12.701

3.  The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair.

Authors:  Claus Storgaard Sørensen; Lasse Tengbjerg Hansen; Jaroslaw Dziegielewski; Randi G Syljuåsen; Cecilia Lundin; Jiri Bartek; Thomas Helleday
Journal:  Nat Cell Biol       Date:  2005-01-23       Impact factor: 28.824

4.  CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers.

Authors:  F Bertoni; A M Codegoni; D Furlan; M G Tibiletti; C Capella; M Broggini
Journal:  Genes Chromosomes Cancer       Date:  1999-10       Impact factor: 5.006

5.  p16INK4a modulates p53 in primary human mammary epithelial cells.

Authors:  Jianmin Zhang; Curtis R Pickering; Charles R Holst; Mona L Gauthier; Thea D Tlsty
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

6.  Chk1 is haploinsufficient for multiple functions critical to tumor suppression.

Authors:  Michael H Lam; Qinghua Liu; Stephen J Elledge; Jeffrey M Rosen
Journal:  Cancer Cell       Date:  2004-07       Impact factor: 31.743

7.  Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A.

Authors:  Geoffrey P Shouse; Xin Cai; Xuan Liu
Journal:  Mol Cell Biol       Date:  2007-10-29       Impact factor: 4.272

8.  Chk1 complements the G2/M checkpoint defect and radiosensitivity of ataxia-telangiectasia cells.

Authors:  P Chen; M Gatei; M J O'Connell; K K Khanna; S J Bugg; A Hogg; S P Scott; K Hobson; M F Lavin
Journal:  Oncogene       Date:  1999-01-07       Impact factor: 9.867

9.  Chk1 deficiency in the mouse small intestine results in p53-independent crypt death and subsequent intestinal compensation.

Authors:  K R Greenow; A R Clarke; R H Jones
Journal:  Oncogene       Date:  2009-01-26       Impact factor: 9.867

Review 10.  G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer.

Authors:  N Bucher; C D Britten
Journal:  Br J Cancer       Date:  2008-01-29       Impact factor: 7.640

View more
  9 in total

Review 1.  microRNAs in cancer cell response to ionizing radiation.

Authors:  Jennifer R Czochor; Peter M Glazer
Journal:  Antioxid Redox Signal       Date:  2014-02-04       Impact factor: 8.401

2.  Fluvastatin sensitizes pancreatic cancer cells toward radiation therapy and suppresses radiation- and/or TGF-β-induced tumor-associated fibrosis.

Authors:  Debasish Mohapatra; Biswajit Das; Voddu Suresh; Deepti Parida; Aliva Prity Minz; Usharani Nayak; Amlan Priyadarshee Mohapatra; Rajeeb K Swain; Shantibhusan Senapati
Journal:  Lab Invest       Date:  2021-11-12       Impact factor: 5.662

3.  Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.

Authors:  Yuxia Cui; Stela S Palii; Cynthia L Innes; Richard S Paules
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

4.  Intrinsic mitochondrial DNA repair defects in Ataxia Telangiectasia.

Authors:  Nilesh K Sharma; Maria Lebedeva; Terace Thomas; Olga A Kovalenko; Jeffrey D Stumpf; Gerald S Shadel; Janine H Santos
Journal:  DNA Repair (Amst)       Date:  2013-12-15

5.  Compensation, crosstalk and sequestering: the currency of checkpoints in cancer.

Authors:  William K Kaufmann; Carl W Anderson
Journal:  Cell Cycle       Date:  2013-04-02       Impact factor: 4.534

6.  Suppression of Vimentin Phosphorylation by the Avian Reovirus p17 through Inhibition of CDK1 and Plk1 Impacting the G2/M Phase of the Cell Cycle.

Authors:  Hung-Chuan Chiu; Wei-Ru Huang; Tsai-Ling Liao; Hung-Yi Wu; Muhammad Munir; Wing-Ling Shih; Hung-Jen Liu
Journal:  PLoS One       Date:  2016-09-07       Impact factor: 3.240

7.  The G2 checkpoint-a node-based molecular switch.

Authors:  Mark C de Gooijer; Arnout van den Top; Irena Bockaj; Jos H Beijnen; Thomas Würdinger; Olaf van Tellingen
Journal:  FEBS Open Bio       Date:  2017-03-04       Impact factor: 2.693

8.  Regulation of cardiomyocyte DNA damage and cell death by the type 2A protein phosphatase regulatory protein alpha4.

Authors:  Jonathan Cowan; Michael R Longman; Andrew K Snabaitis
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379

Review 9.  Targeting Cell Cycle Checkpoint Kinases to Overcome Intrinsic Radioresistance in Brain Tumor Cells.

Authors:  Tijana Vlatkovic; Marlon R Veldwijk; Frank A Giordano; Carsten Herskind
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.